These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 12083481

  • 1. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
    Marciniak SJ, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL.
    Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
    [Abstract] [Full Text] [Related]

  • 2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 3. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.
    Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, White MM, Jennings LK.
    J Thromb Haemost; 2009 Jun; 7(6):983-91. PubMed ID: 19548907
    [Abstract] [Full Text] [Related]

  • 4. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
    Weber AA, Schrör K.
    Blood; 2001 Sep 01; 98(5):1619-21. PubMed ID: 11520817
    [Abstract] [Full Text] [Related]

  • 5. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
    Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ, Sobel BE.
    Thromb Haemost; 2001 Feb 01; 85(2):309-13. PubMed ID: 11246553
    [Abstract] [Full Text] [Related]

  • 6. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 01; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 7. Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban.
    Frojmovic M, Labarthe B, Legrand C.
    Br J Haematol; 2005 Nov 01; 131(3):348-55. PubMed ID: 16225655
    [Abstract] [Full Text] [Related]

  • 8. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM, Buckland RJ, Holgate CE, Storey RF.
    Platelets; 2005 Nov 01; 16(7):398-407. PubMed ID: 16236601
    [Abstract] [Full Text] [Related]

  • 9. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK, Whitaker DA, Sobel BE, Schneider DJ.
    Thromb Res; 2004 Nov 01; 113(1):27-34. PubMed ID: 15081562
    [Abstract] [Full Text] [Related]

  • 10. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression.
    Scazziota A, Altman R, Rouvier J, Gonzalez C, Ahmed Z, Jeske WP, Walenga JM, Fareed J.
    Thromb Res; 2000 Dec 15; 100(6):479-88. PubMed ID: 11152927
    [Abstract] [Full Text] [Related]

  • 11. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 12. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF.
    J Am Coll Cardiol; 1995 Dec 14; 26(7):1665-71. PubMed ID: 7594101
    [Abstract] [Full Text] [Related]

  • 13. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2001 May 14; 297(2):496-500. PubMed ID: 11303035
    [Abstract] [Full Text] [Related]

  • 14. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M, Bertram U, Peter K, Bode C, Ruef J.
    J Cardiovasc Pharmacol; 2003 Apr 14; 41(4):586-92. PubMed ID: 12658060
    [Abstract] [Full Text] [Related]

  • 15. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ, Agneskirchner J, Bode PA, Spannagl M, Wurzinger LJ.
    Thromb Haemost; 2000 Feb 14; 83(2):217-23. PubMed ID: 10739376
    [Abstract] [Full Text] [Related]

  • 16. Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.
    Speich HE, Furman RR, Lands LT, Moodie GD, Jennings LK.
    J Thromb Thrombolysis; 2013 Jul 14; 36(1):31-41. PubMed ID: 23073747
    [Abstract] [Full Text] [Related]

  • 17. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.
    Circulation; 1999 May 04; 99(17):2231-8. PubMed ID: 10226086
    [Abstract] [Full Text] [Related]

  • 18. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 04; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 19. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
    Steiner S, Seidinger D, Huber K, Kaun C, Minar E, Kopp CW.
    Arterioscler Thromb Vasc Biol; 2003 Sep 01; 23(9):1697-702. PubMed ID: 12869353
    [Abstract] [Full Text] [Related]

  • 20. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
    Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF.
    Circulation; 2000 Mar 07; 101(9):1013-8. PubMed ID: 10704169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.